No products in the cart.
Pre-made Enapotamab benchmark antibody ( Whole mAb ADC, anti-AXL therapeutic antibody, Anti-ARK/UFO/JTK11/Tyro7 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-179
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Enapotamab biosimilar, Whole mAb ADC, Anti-AXL Antibody: Anti-ARK/UFO/JTK11/Tyro7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Enapotamab vedotin (HuMax?-AXL-ADC) is an antibody-drug conjugate (ADC) targeted to Axl (from anexelekto, or uncontrolled growth). Axl is a unique RTK that is aberrantly expressed in many solid tumor types and is implicated in tumor cell proliferation, migration, and invasion.
| Products Name (INN Index) | Pre-Made Enapotamab biosimilar, Whole mAb ADC, Anti-AXL Antibody: Anti-ARK/UFO/JTK11/Tyro7 therapeutic antibody |
|---|---|
| INN Name | Enapotamab |
| Target | AXL |
| Format | Whole mAb ADC |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Genmab |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | AXL |
| Package |
Previous slide
Next slide
